Mutations in the HLA class II genes leading to loss of expression of HLA-DR and HLA-DQ in diffuse large B-cell lymphoma
暂无分享,去创建一个
Ed Schuuring | Philip M. Kluin | E. Jordanova | E. Schuuring | P. Kluin | M. Giphart | K. Philippo | Ekaterina S. Jordanova | Katja Philippo | Marius J. Giphart
[1] O. Olerup,et al. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. , 1992, Tissue antigens.
[2] Hishii,et al. Studies of the mechanism of cytolysis by tumour‐infiltrating lymphocytes , 1999, Clinical and experimental immunology.
[3] W. Vainchenker,et al. Immunological study of in vitro maturation of human megakaryocytes , 1984, British journal of haematology.
[4] C. Benoist,et al. Regulation of major histocompatibility complex class-II genes: X, Y and other letters of the alphabet. , 1990, Annual review of immunology.
[5] Santa Jeremy Ono,et al. HLA-DRA promoter polymorphism and diversity generation within the immune system , 1997, Human Genetics.
[6] E. Albert,et al. A deletion in the second exon of an HLA-DRB1 allele found in a DR2-negative narcolepsy patient. , 1993, Human immunology.
[7] J. Harton,et al. Class II Transactivator: Mastering the Art of Major Histocompatibility Complex Expression , 2000, Molecular and Cellular Biology.
[8] E. Jordanova,et al. Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites. , 2000, Blood.
[9] G. Nepom,et al. Ultrastructural allelic variation in HLA-DQB1 promoter elements. , 1995, Human immunology.
[10] S. Westerheide,et al. The MHC-Specific Enhanceosome and Its Role in MHC Class I and β2-Microglobulin Gene Transactivation1 , 2001, The Journal of Immunology.
[11] S G Marsh,et al. HLA class II region sequences, 1998. , 2008, Tissue antigens.
[12] Julia G. Bodmer,et al. IMGT/HLA Database--a sequence database for the human major histocompatibility complex. , 2001, Nucleic acids research.
[13] E. Jordanova,et al. Hemizygous deletions in the HLA region account for loss of heterozygosity in the majority of diffuse large B‐cell lymphomas of the testis and the central nervous system , 2002, Genes, chromosomes & cancer.
[14] W R Mayr,et al. Nomenclature for factors of the HLA system, 2002. , 2002, Tissue antigens.
[15] G. Fleuren,et al. Multiple Genetic Alterations Cause Frequent and Heterogeneous Human Histocompatibility Leukocyte Antigen Class I Loss in Cervical Cancer , 2000, The Journal of experimental medicine.
[16] L. Glimcher,et al. Sequences and factors: a guide to MHC class-II transcription. , 1992, Annual review of immunology.
[17] O. Olerup,et al. HLA‐DQB1 and ‐DQA1 typing by PCR amplification with sequence‐specific primers (PCR‐SSP) in 2 hours , 1993 .
[18] J. Freed,et al. Ligation of major histocompatibility complex class II molecules mediates apoptotic cell death in resting B lymphocytes. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[19] T. Ottenhoff,et al. Mycobacterium leprae-Specific, HLA Class II-Restricted Killing of Human Schwann Cells by CD4+ Th1 Cells: A Novel Immunopathogenic Mechanism of Nerve Damage in Leprosy1 , 2001, The Journal of Immunology.
[20] P. A. Peterson,et al. HLA-DR beta genes vary in number between different DR specificities, whereas the number of DQ beta genes is constant. , 1985, Journal of immunology.
[21] R. Doebele,et al. Novel glycosylation of HLA-DRalpha disrupts antigen presentation without altering endosomal localization. , 1998, Journal of immunology.
[22] M. Kagnoff,et al. Differential expression of HLA-DQA1 alleles associated with promoter polymorphism , 1997, Immunogenetics.
[23] Steven G.E. Marsh,et al. Nomenclature for factors of the HLA system , 1975 .
[24] D. Vidovic,et al. Selective apoptosis of neoplastic cells by the HLA-DR-specific monoclonal antibody. , 1998, Cancer letters.
[25] F. Garrido,et al. Rexpression of HLA class I antigens and restoration of antigen‐specific CTL response in melanoma cells following 5‐aza‐2′‐deoxycytidine treatment , 2001, International journal of cancer.
[26] F. Bach,et al. Detection of a novel human class II HLA antigen , 1983, Nature.
[27] W. Reith,et al. The bare lymphocyte syndrome and the regulation of MHC expression. , 2001, Annual review of immunology.
[28] P. Stern,et al. Multiple mechanisms underlie HLA dysregulation in cervical cancer. , 2000, Tissue antigens.
[29] F. Garrido,et al. MHC antigens and tumor escape from immune surveillance. , 2001, Advances in cancer research.
[30] J. Trowsdale,et al. Genetic Control of MHC Class II Expression , 2002, Cell.
[31] M. Chamberlain,et al. T-cell infiltration of primary CNS lymphoma , 1996, Neurology.
[32] M. Kagnoff,et al. Structure and evolution of the promoter regions of the DQA genes , 2004, Immunogenetics.
[33] S. Stevanović,et al. Epstein-Barr Nuclear Antigen 1-Specific CD4+ Th1 Cells Kill Burkitt’s Lymphoma Cells1 , 2002, The Journal of Immunology.
[34] H. Petrie,et al. CD4+ T cells kill HLA-class-II-antigen-positive melanoma cells presenting peptide in vitro , 2000, Cancer Immunology, Immunotherapy.
[35] G. Yang,et al. DNA hypermethylation is a mechanism for loss of expression of the HLA class I genes in human esophageal squamous cell carcinomas. , 2001, Carcinogenesis.
[36] M. Tesar,et al. Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells , 2002, Nature Medicine.
[37] S. Kroft,et al. Prognostic significance of tumour‐infiltrating T lymphocytes and T‐cell subsets in de novo diffuse large B‐cell lymphoma: a multiparameter flow cytometry study , 2001, British journal of haematology.
[38] W. Reith,et al. Promoter‐specific functions of CIITA and the MHC class II enhanceosome in transcriptional activation , 2002, The EMBO journal.
[39] Dominique Charron,et al. Three novel mutations of the CIITA gene in MHC class II-deficient patients with a severe immunodeficiency , 2002, Immunogenetics.
[40] T. Habermann,et al. Cd4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.